Revvity has announced that its Revvity Signals Software business has entered into a strategic relationship with Scitara – a leading global provider of cloud-based solutions for the scientific industry. Together, the companies will transform the way R&D teams work across the biotech, pharmaceutical and chemical industries with technology that accelerates digital transformation in the laboratory.
PathAI has announced the availability of AIM-HER2 Breast Cancer for research use by clinical laboratories, researchers, and drug developers. AIM-HER2 Breast Cancer delivers automated digital HER2 scoring and is the market’s first algorithm to use additive multiple instance learning (aMIL) heatmaps to visualise the slide features driving the algorithm’s predicted score.
Anbio has introduced a comprehensive RT-PCR solution that encompasses both pharmacogenomic and non-pharmacogenomic applications. The Anbio molecular diagnostic test menu spans multiple clinical applications including healthcare-associated infections, critical infectious disease, sexual health, virology, pharmacogenomics, and oncology.
Point-of-care diagnostics firm QuidelOrtho has entered into a software development partnership with BYG4lab, a leading provider of middleware and data management solutions for laboratories, that intends to accelerate QuidelOrtho’s efforts to expand and strengthen informatics offerings across its portfolio of diagnostics platforms.
Proteomic and glycomic research firm Vector Laboratories has announced the acquisition of Quanta BioDesign, the inventor of discrete polyethylene glycol (dPEG) technology for advanced bioconjugate and payload delivery design for life science and biopharma applications.
Cleanroom laboratories manufacturing sterile medicinal products in the European Union (EU) must make critical changes by 25 August 2023 to ensure Annex 1 Regulation compliance and Beckman Coulter Life Sciences is continuing its commitment to providing laboratories of all sizes with tailored support to meet the evolving list of regional and global compliance requirements.
Revvity has announced the launch of the Fontus Automated Liquid Handling Workstation, a next-generation liquid handler incorporating the best technologies from Revvity’s existing platforms, designed to deliver easier and faster workflows for next-generation sequencing (NGS) and diagnostic research applications.
Beckman Coulter Diagnostics and Fujirebio, a leader in neurological markers and in vitro diagnostic (IVD) manufacturing, have announced a new partnership combining their respective immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases.
Illumina in collaboration with Nashville Biosciences, has announced the five founding members of the Alliance for Genomic Discovery (AGD). Member organisations AbbVie, Amgen, AstraZeneca, Bayer, and Merck have joined the multiyear agreement aiming to accelerate development of therapeutics through large-scale genomics and the establishment of a preeminent clinical genomic resource.
HNL Lab Medicine, a leading multi-regional US-based clinical diagnostics laboratory, has made a groundbreaking investment in digital pathology, having selected solutions from Proscia, a digital pathology software company, and Leica Biosystems, a manufacturer of high-quality imaging hardware, to establish an advanced digital pathology practice.
Quest Diagnostics has launched a novel prostate cancer biomarker test through its subspecialty pathology business, AmeriPath, in collaboration with Envision Sciences. The new, tissue-based test service is intended to address the pressing clinical need for tests to help identify and differentiate potentially aggressive cases of prostate cancer in men.
To extend the benefits of genomic testing research for reproductive health laboratories, Thermo Fisher Scientific has launched two new next-generation sequencing-based options to support preimplantation genetic testing-aneuploidy (PGT-A) used commonly to inform in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI) research.
New HIV transmissions in England have fallen by almost a third since 2019, while fewer people remain unaware of their HIV status as a result of increased testing across the country, according to an update on the HIV Action Plan for England published recently.
Lonza has launched the TheraPRO CHO media system, a new cell-culture platform that simplifies processes and optimises productivity and protein quality when used with GS-CHO cell lines. The launch supports pharmaceutical and biotechnology companies manufacturing therapeutic proteins to further improve product quality while streamlining time to market.
Thermo Fisher Scientific has introduced Diomni Enterprise software to address challenges with manual molecular testing workflows, with the aim of helping streamline routine diagnostics testing for standardisation and faster results.
Global health science solutions company Revvity has announced the establishment of a Scientific Centre of Excellence in Cambridge, UK. Focused on driving genomic insights to accelerate therapeutic discovery, Revvity’s Scientific Centre of Excellence supports the company’s commitment to expanding boundaries in pursuit of a better future for human health.
Orgenesis, a global biotech company working in cell and gene therapies (CGT) at the point of care, has announced the name change of the POC Services business from Morgenesis to Octomera, effective 30 June 2023, to reflect the growth and focus on providing advanced CGT services, facilities, and technologies.
A new Corporate Plan, setting out how the Medicines and Healthcare products Regulatory Agency (MHRA) plans to keep patients safe by enabling access to innovative, safe and effective medical products over the coming three years, has been published.
The Microbiology Society has welcomed the opportunity from the House of Commons Science and Technology Committee to respond to the inquiry on emerging diseases and lessons learned from COVID-19. The Society consulted with its members that were directly involved in the national response to the pandemic to co-ordinate its response.
NK:IO, a leader in NK cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumours, has been awarded £1.6 million in grant funding from Innovate UK’s New Cancer Therapeutics programme.